BioVie Inc. (NASDAQ: BIVI)

BIVI · Nasdaq · United States

Share price · BIVI

$0.94-0.02 (-2.24%) 3M

close as of 2026-11-18 · 24h delayed · vol 187K (0.3x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when BIVI's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 4 Nov 2026-22.5%
  2. 3 Nov 2026+26.3%
  3. 20 Aug 2026+38.8%

    Nothing announced by BIVI that day or the session before.

  4. 19 Aug 2026+38.9%

    Nothing announced by BIVI that day or the session before.

  5. 12 Aug 2026+22.8%

    Nothing announced by BIVI that day or the session before.

  6. 7 Aug 2026-26.0%
  7. 6 Aug 2026-33.8%
  8. 20 Jul 2026-20.8%

    Nothing announced by BIVI that day or the session before.

  9. 13 Jul 2026-27.8%
  10. 2 Jul 2026-10.6%

Share of unusual movement by asset

For each asset, the share of BIVI's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Bezisterim
events and moves
157%
Other company news (earnings, financing, releases naming no asset)—15%
Sessions with no dated event—78%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
ERK/NF-kB inflammatorySmall molecule
Alzheimer's DiseaseParkinson's Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

19 October 2026Topline resultBezisterimADDRESS-LC Phase 2 results reported
15 September 2026Topline resultBezisterimPhase 2 ADDRESS-LC (NCT06847191) topline of bezisterim in Long COVID: no endpoint significant in the overall population
BioVie Inc. (NASDAQ: BIVI) · Source ↗
6 August 2026Topline resultBezisterimPhase 2 SUNRISE-PD topline in early Parkinson's disease (sponsor-reported)
BioVie Inc. · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$3.3M$7.7M$5.6M-$2.9M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1—$3.2M$13M$5.3M-$7.4M operating cash flowreport ↗
2025-Q4—$4.3M$21M$6.1M-$4.4M operating cash flowreport ↗
2025-Q3—$2.9M$25M$5.1M-$3.0M operating cash flowreport ↗
2025-Q1—$1.3M$23M$2.8M-$1.3M operating cash flowreport ↗
2024-Q4—$4.7M$24M$7.1M-$8.6M operating cash flowreport ↗
2024-Q3—$2.0M$20M$4.2M-$3.6M operating cash flowreport ↗
2024-Q1—$5.7M$30M$8.1M-$5.8M operating cash flowreport ↗
2023-Q4—$6.5M$20M$8.4M-$5.9M operating cash flowreport ↗
2023-Q3—$8.9M$21M$11M-$12M operating cash flowreport ↗
2023-Q1—$11M$31M$15M-$12M operating cash flowreport ↗
2022-Q4—$7.0M$46M$16M-$8.0M operating cash flowreport ↗
2022-Q3—$6.8M$21M$10M-$9.2M operating cash flowreport ↗
2022-Q1—$3.6M$25M$7.0M-$5.9M operating cash flowreport ↗
2021-Q4—$4.6M$30M$5.4M-$4.7M operating cash flowreport ↗
2021-Q3—$2.9M$20M$5.5M-$2.5M operating cash flowreport ↗

Annual history (6 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-FY—$14M$9.0M$5.5M-$19M operating cash flowreport ↗
View 5 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$9.3M$18M$4.4M-$19M operating cash flowreport ↗
2024-FY—$23M$24M$8.0M-$28M operating cash flowreport ↗
2023-FY—$33M$19M$13M-$40M operating cash flowreport ↗
2022-FY—$17M$19M$6.5M-$19M operating cash flowreport ↗
2021-FY—$133M$4.5M$33M-$10M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 6 purchases ($55K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-18DO CUONG V · director, President & CEOOpen-market purchase2,500$1.00$2KForm 4
2026-11-13DO CUONG V · director, President & CEOOpen-market purchase2,500$1.16$3KForm 4
2026-08-28KIM JOANNE WENDY · Chief Financial OfficerOpen-market purchase2,500$2.18$5KForm 4
2026-08-28Chappell Amy Suzon · directorOpen-market purchase727$2.16$2KForm 4
2026-08-28Palumbo Joseph M · Chief Medical OfficerOpen-market purchase4,843$2.16$10KForm 4
2026-08-27DO CUONG V · director, President & CEOOpen-market purchase15,210$2.08$32KForm 4
2026-01-05Lang James Paul · directorAward / grant (derivative)90,000——Form 4
2026-01-05Chappell Amy Suzon · directorAward / grant (derivative)57,500——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 32 reporting institutions held 1.0M shares ($1.3M, 13.7% of shares outstanding).

#InstitutionSharesValue
1Diametric Capital, LP370,000$518K
2PRELUDE CAPITAL MANAGEMENT, LLC92,063$129K
3GEODE CAPITAL MANAGEMENT, LLC84,203$118K
4VANGUARD CAPITAL MANAGEMENT LLC84,067$118K
5MORGAN STANLEY75,221$105K
6RENAISSANCE TECHNOLOGIES LLC67,918$95K
7CITADEL ADVISORS LLC45,292$63K
8VANGUARD FIDUCIARY TRUST CO37,557$53K
9JANE STREET GROUP, LLC22,791$32K
10XTX Topco Ltd21,226$30K
11NORTHERN TRUST CORP14,189$20K
12Tower Research Capital LLC (TRC)7,540$11K
13Allworth Financial LP5,600$8K
14CITIGROUP INC3,164$4K
15PNC FINANCIAL SERVICES GROUP, INC.1,000$1K